[Effects of FOY-305 on post-operative reflux esophagitis in rats (I). Effects of FOY-305 on reflux esophagitis after total gastrectomy in rats].
We investigated the effect of camostat mesilate (FOY-305), an oral protease inhibitor, on reflux esophagitis after total gastrectomy followed by an end-to-side esophago-jejunostomy (Billroth-II) in rats. Effects of FOY-305 were compared with those of sodium alginate (AL-Na) and cimetidine. On the basis that esophageal ulceration occurred from post-operative day 5 in this model, rodents were fed with special chows containing test drugs from day 2 for 5 or 12 days in order to examine the prophylactic effects (Exp. I) and from day 7 for two weeks in healing experiments (Exp. II). In Exp. I, FOY-305 significantly prevented esophageal ulceration on post-operative days 7 and 14. However, AL-Na significantly prevented esophageal ulceration on post-operative day 7 but not on day 14. In Exp. II, FOY-305 had a remarkable therapeutic effect on esophageal ulceration on day 21. Food intake and body weight of rodents in the FOY-305-treated group were higher than those in the control group. In pathohistological studies, FOY-305 elicited an inhibitory effect on ulceration and induced esophageal mucosal regeneration at the ulceration sites. In contrast, AL-Na and cimetidine did not have any significant therapeutic effect. These results suggest that FOY-305 is an effective agent for the treatment of reflux esophagitis after total gastrectomy.
Kamiyasu
K
K
Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Awata
H
H
Inoshiri
S
S
Doi
A
A
Omawari
N
N
Okegawa
T
T
Kawasaki
A
A
Shinomiya
K
K
Tanaka
M
M
Suzuki
Y
Y
D000464:Alginates / Q000627:therapeutic use; D000818:Animals; D001835:Body Weight; D002927:Cimetidine / Q000627:therapeutic use; D004195:Disease Models, Animal; D004942:Esophagitis, Peptic / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D004952:Esters; D016670:Gabexate / Q000031:analogs & derivatives*; D005743:Gastrectomy / Q000009:adverse effects*; D020723:Glucuronic Acid; D006146:Guanidines / Q000627:therapeutic use*; D006603:Hexuronic Acids; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control; D051381:Rats; D011919:Rats, Inbred Strains
D000464:Alginates; D004952:Esters; D006146:Guanidines; D006603:Hexuronic Acids; C034532:camostat; D016670:Gabexate; D002927:Cimetidine; D020723:Glucuronic Acid